Neurofit to Participate in Two Congresses.
25 July 2007
Neurofit's head of research Dr Emile Andriambeloson will be attending the 12th biannual meeting of the European Behavioural Pharmacology Society between August 31 and September 03, 2007, at Tbingen, Germany. Dr Andriambeloson will show the effect of BNC-210 – a novel compound with potent anxiolytic activity.
Neurofit will also be present at the 23rd Congress of the European Committee for Treatment and Research of Multiple Sclerosis. This joint meeting will be held in Prague, Czech Republic, between October 11 and 14, 2007. Neurofit's poster will describe the in-vivo effect of BNC-245, a potential new drug for the treatment of multiple sclerosis.
If you need further information, please do not hesitate to contact us. For a complete listing of Neurofit offer, please refer to our website.
